IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $2.80B
• Dividend Yield: N/A
• Average Volume (3M): 1.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: 5376.27%
• EPS Growth: 20.97%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.47
• Shares Outstanding: 87,666,405
• 10 Day Avg. Volume: 925,766
• 30 Day Avg. Volume: 1,207,472
• PEG Ratio: -0.11
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 299.87
• P/FCF Ratio: -8.35
• Enterprise Value/Market Cap: 0.60
• Enterprise Value/Revenue: 7.82
• Enterprise Value/Gross Profit: 7.97
• Enterprise Value/Ebitda: -10.73
• 1Y Price Target: $48.53
• Price Target Upside: 52.51% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $30.00 ▼(-5.72% Downside)

IDEAYA Biosciences' overall stock score is primarily impacted by its financial performance, which highlights significant challenges due to declining revenues and consistent net losses. The technical analysis shows moderate bullish momentum, providing some positive outlook. However, the valuation remains a concern due to the negative P/E ratio and lack of dividend yield.

Positive Factors

Strong Equity Position

A strong equity position with minimal leverage provides financial stability, allowing the company to withstand operational challenges and invest in growth opportunities.

Strategic Partnerships

Strategic partnerships provide financial support and access to resources, enhancing drug development capabilities and potential revenue streams.

Revenue Growth

Significant revenue growth indicates successful product development and market acceptance, supporting long-term business expansion.

Negative Factors

Declining Revenues

A sharp decline in revenue poses a risk to financial sustainability, necessitating strategic adjustments to reverse the trend and achieve profitability.

Negative Cash Flow

Negative cash flow from operations can limit investment in R&D and growth initiatives, requiring careful financial management to maintain liquidity.

Profitability Challenges

Persistent profitability issues highlight operational inefficiencies, necessitating cost management and revenue enhancement strategies to achieve financial health.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

IDEAYA Biosciences generates revenue through a combination of its own product development efforts and strategic partnerships. The company primarily earns money by advancing its pipeline of drug candidates through various stages of clinical trials, leading to potential commercialization. Additionally, IDEAYA enters into collaborations and licensing agreements with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future sales. These partnerships not only offer financial support but also access to resources and expertise necessary for efficient drug development. The company may also receive funding through grants and investments to support its research initiatives.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	214.83M	7.00M	23.39M	50.93M	27.94M	19.54M
Gross Profit	210.79M	3.17M	19.38M	48.83M	26.22M	18.16M
EBITDA	-156.70M	-270.64M	-108.95M	-56.55M	-48.04M	-33.11M
Net Income	-160.74M	-274.48M	-112.96M	-58.66M	-49.76M	-34.49M
Balance Sheet
Total Assets	1.19B	1.12B	649.32M	387.97M	381.35M	298.27M
Cash, Cash Equivalents and Short-Term Investments	786.89M	676.32M	525.11M	364.83M	246.77M	283.58M
Total Debt	27.25M	19.17M	2.87M	3.48M	5.18M	6.72M
Total Liabilities	93.10M	64.94M	28.23M	38.51M	79.83M	100.00M
Stockholders Equity	1.09B	1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow
Free Cash Flow	-105.39M	-251.44M	-117.59M	-90.62M	-58.42M	54.97M
Operating Cash Flow	-102.26M	-247.58M	-115.22M	-87.17M	-55.78M	55.46M
Investing Cash Flow	-29.61M	-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
Financing Cash Flow	30.40M	677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 31.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 31.82 is above the 20-day moving average (MA) of 30.73, above the 50-day MA of 28.01, and above the 200-day MA of 22.64, indicating a bullish trend. The MACD of 1.01 indicates Positive momentum. The RSI at 61.28 is Neutral, neither overbought nor oversold. The STOCH value of 79.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGIO	59 Neutral	$2.54B	―	-27.57%	―	36.26%	-158.98%
ARQT	59 Neutral	$2.87B	―	-28.17%	―	129.21%	80.35%
TVTX	54 Neutral	$3.26B	―	-410.78%	―	114.22%	77.02%
IDYA	53 Neutral	$2.80B	―	-14.15%	―	5376.27%	20.97%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CELC	44 Neutral	$3.61B	―	-122.04%	―	―	-40.75%
BEAM	40 Neutral	$2.22B	-4.88	-47.19%	―	-84.07%	-157.71%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Reports Strong Q3 2025 Results

IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing targeted therapies for cancer, utilizing expertise in small-molecule drug discovery and bioinformatics to address genetic drivers of disease. The company has reported its financial results for the third quarter of 2025, highlighting significant progress in its clinical trials and strategic partnerships.

IDEAYA Biosciences Presents Promising Phase 2 Data

On October 17, 2025, IDEAYA Biosciences announced positive median overall survival data from its Phase 1/2 trial of darovasertib combined with Pfizer’s crizotinib for first-line treatment of metastatic uveal melanoma, showing a median OS of 21.1 months. Additionally, on October 20, 2025, IDEAYA presented promising Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma, demonstrating significant tumor shrinkage and eye preservation, with manageable safety profiles.

The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Ideaya Biosciences Advances IDE849 Study for DLL3-Expressing Tumors

Ideaya Biosciences is conducting a clinical study titled ‘A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer.’ The study aims to assess the safety and effectiveness of IDE849, a potential treatment for tumors expressing DLL3, particularly small cell lung cancer (SCLC). This research is significant as it explores new therapeutic options for a challenging cancer type.

IDEAYA Biosciences Reports Promising Phase 1 Data for IDE849

IDEAYA Biosciences, in collaboration with Jiangsu Hengrui Pharmaceuticals, presented promising Phase 1 data for IDE849, a DLL3-targeting TOP1 ADC, at the IASLC 2025 World Conference on Lung Cancer. The trial showed a robust overall response rate and disease control rate in small cell lung cancer patients, with manageable safety profiles across various dose levels. Additionally, IDEAYA shared positive interim results from its Phase 2 trial of darovasertib for primary uveal melanoma, demonstrating significant tumor shrinkage and improved visual outcomes. The company also reported encouraging data from its Phase 1/2 trial of IDE397 combined with Trodelvy in MTAP-deletion urothelial cancer, highlighting a favorable safety profile and notable response rates.

The most recent analyst rating on (IDYA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Ideaya Biosciences Advances in Metastatic Uveal Melanoma Treatment Study

Ideaya Biosciences is conducting a clinical study titled ‘IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).’ The study aims to evaluate the efficacy of IDE196 combined with Crizotinib compared to standard treatments for patients with metastatic uveal melanoma, a rare eye cancer. This research is significant as it explores a new potential first-line treatment option for this challenging condition.

IDEAYA Biosciences Licenses Darovasertib to Servier

On August 29, 2025, IDEAYA Biosciences entered into a License Agreement with Les Laboratoires Servier, granting Servier exclusive rights to develop and commercialize darovasertib outside the United States. This agreement includes an upfront payment of $210 million to IDEAYA, with potential additional milestone payments and royalties, extending the company’s cash runway by at least twelve months and funding operations into 2030. The agreement outlines conditions for termination and includes customary transaction provisions.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.